Reduced platelet vesicular monoamine transporter density in Tourette's syndrome pediatric male patients

David H. Ben-Dor; Sharon Zimmerman; Jonathan Sever; Neta Roz; Alan Apter; Moshe Rehavi; Abraham Weizman

doi:10.1016/j.euroneuro.2007.01.002

Reduced platelet vesicular monoamine transporter density in Tourette's syndrome pediatric male patients

David H. Ben-Dor
, Sharon Zimmerman
, Jonathan Sever
, Neta Roz
, Alan Apter
, Moshe Rehavi
, Abraham Weizman

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The vesicular monoamine transporter (VMAT2) plays a major role in the synaptic accumulation and quantal release of monoamines. In this study, we assessed high affinity [³H]dihydrotetrabenazine binding to platelet VMAT2, in a group of untreated male Tourette's syndrome (TS) patients (age: 8-17.5 years, n = 9) and in a group of age- and sex-matched healthy controls (age: 9-16 years, n = 16). Significantly decreased platelet VMAT2 density (B_max) (- 23%, p = 0.016) was observed in the TS patients. The affinity (K_d) of the ligand to platelet VMAT2 was similar in both groups. If the lower platelet VMAT2 density also occurred in the brain, it may have serve as an adaptive mechanism geared to decrease dopamine storage in the presynaptic neurons and thereby to attenuate the dopaminergic overactivity and ameliorate the movement disorder.

Original language	English
Pages (from-to)	523-526
Number of pages	4
Journal	European Neuropsychopharmacology
Volume	17
Issue number	8
DOIs	https://doi.org/10.1016/j.euroneuro.2007.01.002
State	Published - Jul 2007
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Attention deficit hyperactivity disorder
Obsessive-compulsive disorder (OCD)
Platelet
Tourette's syndrome
Vesicular monoamine transporter 2 (VMAT2)

Access to Document

10.1016/j.euroneuro.2007.01.002

Cite this

@article{d92bf43d984a423bb31cbf97a3d209d9,

title = "Reduced platelet vesicular monoamine transporter density in Tourette's syndrome pediatric male patients",

abstract = "The vesicular monoamine transporter (VMAT2) plays a major role in the synaptic accumulation and quantal release of monoamines. In this study, we assessed high affinity [3H]dihydrotetrabenazine binding to platelet VMAT2, in a group of untreated male Tourette's syndrome (TS) patients (age: 8-17.5 years, n = 9) and in a group of age- and sex-matched healthy controls (age: 9-16 years, n = 16). Significantly decreased platelet VMAT2 density (Bmax) (- 23\%, p = 0.016) was observed in the TS patients. The affinity (Kd) of the ligand to platelet VMAT2 was similar in both groups. If the lower platelet VMAT2 density also occurred in the brain, it may have serve as an adaptive mechanism geared to decrease dopamine storage in the presynaptic neurons and thereby to attenuate the dopaminergic overactivity and ameliorate the movement disorder.",

keywords = "Attention deficit hyperactivity disorder, Obsessive-compulsive disorder (OCD), Platelet, Tourette's syndrome, Vesicular monoamine transporter 2 (VMAT2)",

author = "Ben-Dor, \{David H.\} and Sharon Zimmerman and Jonathan Sever and Neta Roz and Alan Apter and Moshe Rehavi and Abraham Weizman",

year = "2007",

month = jul,

doi = "10.1016/j.euroneuro.2007.01.002",

language = "אנגלית",

volume = "17",

pages = "523--526",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier B.V.",

number = "8",

}

TY - JOUR

T1 - Reduced platelet vesicular monoamine transporter density in Tourette's syndrome pediatric male patients

AU - Ben-Dor, David H.

AU - Zimmerman, Sharon

AU - Sever, Jonathan

AU - Roz, Neta

AU - Apter, Alan

AU - Rehavi, Moshe

AU - Weizman, Abraham

PY - 2007/7

Y1 - 2007/7

N2 - The vesicular monoamine transporter (VMAT2) plays a major role in the synaptic accumulation and quantal release of monoamines. In this study, we assessed high affinity [3H]dihydrotetrabenazine binding to platelet VMAT2, in a group of untreated male Tourette's syndrome (TS) patients (age: 8-17.5 years, n = 9) and in a group of age- and sex-matched healthy controls (age: 9-16 years, n = 16). Significantly decreased platelet VMAT2 density (Bmax) (- 23%, p = 0.016) was observed in the TS patients. The affinity (Kd) of the ligand to platelet VMAT2 was similar in both groups. If the lower platelet VMAT2 density also occurred in the brain, it may have serve as an adaptive mechanism geared to decrease dopamine storage in the presynaptic neurons and thereby to attenuate the dopaminergic overactivity and ameliorate the movement disorder.

AB - The vesicular monoamine transporter (VMAT2) plays a major role in the synaptic accumulation and quantal release of monoamines. In this study, we assessed high affinity [3H]dihydrotetrabenazine binding to platelet VMAT2, in a group of untreated male Tourette's syndrome (TS) patients (age: 8-17.5 years, n = 9) and in a group of age- and sex-matched healthy controls (age: 9-16 years, n = 16). Significantly decreased platelet VMAT2 density (Bmax) (- 23%, p = 0.016) was observed in the TS patients. The affinity (Kd) of the ligand to platelet VMAT2 was similar in both groups. If the lower platelet VMAT2 density also occurred in the brain, it may have serve as an adaptive mechanism geared to decrease dopamine storage in the presynaptic neurons and thereby to attenuate the dopaminergic overactivity and ameliorate the movement disorder.

KW - Attention deficit hyperactivity disorder

KW - Obsessive-compulsive disorder (OCD)

KW - Platelet

KW - Tourette's syndrome

KW - Vesicular monoamine transporter 2 (VMAT2)

UR - https://www.scopus.com/pages/publications/34248589504

U2 - 10.1016/j.euroneuro.2007.01.002

DO - 10.1016/j.euroneuro.2007.01.002

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 17344033

AN - SCOPUS:34248589504

SN - 0924-977X

VL - 17

SP - 523

EP - 526

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

IS - 8

ER -

Reduced platelet vesicular monoamine transporter density in Tourette's syndrome pediatric male patients

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this